| 2021 | | S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma | 박해심, 신유섭, 최영우 |
| 2016 | | Serum Clusterin as a Prognostic Marker of Chronic Spontaneous Urticaria | 박해심, 반가영, 신유섭, 예영민 |
| 2021 | | Serum Human β-Defensin 2 Is Increased in Angioedema Accompanying Chronic Spontaneous Urticaria | 박해심, 예영민 |
| 2013 | | Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. | 김승현, 박해심 |
| 2014 | | Serum specific IgG response to toluene diisocyanate-tissue transglutaminase conjugate in toluene diisocyanate-induced occupational asthmatics. | 박해심, 신유섭 |
| 2021 | | Serum-free immunoglobulin E: A useful biomarker of atopy and type 2 asthma in adults with asthma | 박해심, 신유섭, 예영민, 이영수, 장재혁 |
| 2004 | | Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma. | 김승현, 김현준, 남동호, 박해심, 서창희 |
| 2019 | | Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease | 김승현, 박해심, 신유섭 |
| 2004 | | The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma. | 김승현, 박해심 |
| 2005 | | The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. | 김승현, 남동호, 박해심, 서창희 |
| 2012 | | The impact of total antioxidant capacity on pulmonary function in asthma patients | 남동호 |
| 2015 | | The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity. | 박해심, 반가영, 신유섭, 안영환, 예영민, 최병주 |
| 2000 | | Two-spotted spider mite (Tetranychus urticae): an important allergen in asthmatic non-farmers symtomatic in summer and fall months. | 박해심 |
| 2019 | | Variation of clinical manifestations according to culprit drugs in DRESS syndrome | 예영민 |
| 2018 | | Video education versus face-to-face education on inhaler technique for patients with well-controlled or partly-controlled asthma: A phase IV, open-label, non-inferiority, multicenter, randomized, controlled trial | 남동호 |
